Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

September 30, 2021

Conditions
Acute Hypoxemic Respiratory Failure
Interventions
DRUG

L-Citrulline

L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.

DRUG

Placebo

Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

Sponsors
All Listed Sponsors
lead

Asklepion Pharmaceuticals, LLC

INDUSTRY

NCT04570384 - Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 | Biotech Hunter | Biotech Hunter